These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 26405798)

  • 1. Generation and Characterization of Live Attenuated Influenza A(H7N9) Candidate Vaccine Virus Based on Russian Donor of Attenuation.
    Shcherbik S; Pearce N; Balish A; Jones J; Thor S; Davis CT; Pearce M; Tumpey T; Cureton D; Chen LM; Villanueva J; Bousse TL
    PLoS One; 2015; 10(9):e0138951. PubMed ID: 26405798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a high-yield reassortant influenza vaccine virus derived from the A/Anhui/1/2013 (H7N9) strain.
    Nakamura K; Shirakura M; Suzuki Y; Naito T; Fujisaki S; Tashiro M; Nobusawa E
    Vaccine; 2016 Jan; 34(3):328-33. PubMed ID: 26657023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Single Amino Acid Substitution at Residue 218 of Hemagglutinin Improves the Growth of Influenza A(H7N9) Candidate Vaccine Viruses.
    Li X; Gao Y; Ye Z
    J Virol; 2019 Oct; 93(19):. PubMed ID: 31270231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a high-yield live attenuated H7N9 influenza virus vaccine that provides protection against homologous and heterologous H7 wild-type viruses in ferrets.
    Chen Z; Baz M; Lu J; Paskel M; Santos C; Subbarao K; Jin H; Matsuoka Y
    J Virol; 2014 Jun; 88(12):7016-23. PubMed ID: 24719414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic stability of live attenuated vaccines against potentially pandemic influenza viruses.
    Kiseleva I; Dubrovina I; Fedorova E; Larionova N; Isakova-Sivak I; Bazhenova E; Pisareva M; Kuznetsova V; Flores J; Rudenko L
    Vaccine; 2015 Dec; 33(49):7008-14. PubMed ID: 26432909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Peculiarity of reassortment of current wild type influenza viruses with master donor viruses for live influenza vaccine].
    Kiseleva IV; Bazhenova EA; Larionova NV; Fedorova EA; Dubrovina IA; Isakova-Sivak IN; Rudenko LG
    Vopr Virusol; 2013; 58(5):26-31. PubMed ID: 24640168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of reverse genetics-derived cold-adapted master donor virus A/Leningrad/134/17/57 (H2N2) and reassortants with H5N1 surface genes in a mouse model.
    Isakova-Sivak I; Chen LM; Bourgeois M; Matsuoka Y; Voeten JT; Heldens JG; van den Bosch H; Klimov A; Rudenko L; Cox NJ; Donis RO
    Clin Vaccine Immunol; 2014 May; 21(5):722-31. PubMed ID: 24648485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of an Influenza A Master Virus for Generating High-Growth Reassortants for A/Anhui/1/2013(H7N9) Vaccine Production in Qualified MDCK Cells.
    Suzuki Y; Odagiri T; Tashiro M; Nobusawa E
    PLoS One; 2016; 11(7):e0160040. PubMed ID: 27454606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A live attenuated cold-adapted influenza A H7N3 virus vaccine provides protection against homologous and heterologous H7 viruses in mice and ferrets.
    Joseph T; McAuliffe J; Lu B; Vogel L; Swayne D; Jin H; Kemble G; Subbarao K
    Virology; 2008 Aug; 378(1):123-32. PubMed ID: 18585748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid strategy for screening by pyrosequencing of influenza virus reassortants--candidates for live attenuated vaccines.
    Shcherbik SV; Pearce NC; Levine ML; Klimov AI; Villanueva JM; Bousse TL
    PLoS One; 2014; 9(3):e92580. PubMed ID: 24647786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotypic properties resulting from directed gene segment reassortment between wild-type A/Sydney/5/97 influenza virus and the live attenuated vaccine strain.
    Parks CL; Latham T; Cahill A; O'neill RE; Passarotti CJ; Buonagurio DA; Bechert TM; D'Arco GA; Neumann G; Destefano J; Arendt HE; Obregon J; Shutyak L; Hamm S; Sidhu MS; Zamb TJ; Udem SA
    Virology; 2007 Oct; 367(2):275-87. PubMed ID: 17599381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plant-derived H7 VLP vaccine elicits protective immune response against H7N9 influenza virus in mice and ferrets.
    Pillet S; Racine T; Nfon C; Di Lenardo TZ; Babiuk S; Ward BJ; Kobinger GP; Landry N
    Vaccine; 2015 Nov; 33(46):6282-9. PubMed ID: 26432915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective efficacy of intranasal cold-adapted influenza A/New Caledonia/20/99 (H1N1) vaccines comprised of egg- or cell culture-derived reassortants.
    Palker T; Kiseleva I; Johnston K; Su Q; Toner T; Szymkowiak C; Kwan WS; Rubin B; Petrukhin L; Wlochowski J; Monteiro J; Kraiouchkine N; DiStefano D; Rudenko L; Shaw A; Youil R
    Virus Res; 2004 Oct; 105(2):183-94. PubMed ID: 15351492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 220 mutation in the hemagglutinin of avian influenza A (H7N9) virus alters antigenicity during vaccine strain development.
    Liu L; Lu J; Li Z; Zhou J; Guo J; Li X; Liu J; Shu Y; Wang D
    Hum Vaccin Immunother; 2018 Mar; 14(3):532-539. PubMed ID: 29300686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of influenza A(H7N9) candidate vaccine viruses with improved hemagglutinin antigen yield in eggs.
    Ridenour C; Johnson A; Winne E; Hossain J; Mateu-Petit G; Balish A; Santana W; Kim T; Davis C; Cox NJ; Barr JR; Donis RO; Villanueva J; Williams TL; Chen LM
    Influenza Other Respir Viruses; 2015 Sep; 9(5):263-70. PubMed ID: 25962412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Restriction analysis of genome composition of live influenza vaccine].
    Kiseleva IV; Larionova NV; Teley LC; Rudenko LG
    Vopr Virusol; 2011; 56(3):28-32. PubMed ID: 21786624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative studies of infectivity, immunogenicity and cross-protective efficacy of live attenuated influenza vaccines containing nucleoprotein from cold-adapted or wild-type influenza virus in a mouse model.
    Isakova-Sivak I; Korenkov D; Smolonogina T; Tretiak T; Donina S; Rekstin A; Naykhin A; Shcherbik S; Pearce N; Chen LM; Bousse T; Rudenko L
    Virology; 2017 Jan; 500():209-217. PubMed ID: 27829176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of three live attenuated H2 pandemic influenza vaccine candidates in mice and ferrets.
    Chen GL; Lamirande EW; Cheng X; Torres-Velez F; Orandle M; Jin H; Kemble G; Subbarao K
    J Virol; 2014 Mar; 88(5):2867-76. PubMed ID: 24371061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of real time RT-PCR for the genetic homogeneity and stability tests of the seed candidates for live attenuated influenza vaccine production.
    Shcherbik S; Sergent SB; Davis WG; Shu B; Barnes J; Kiseleva I; Larionova N; Klimov A; Bousse T
    J Virol Methods; 2014 Jan; 195():18-25. PubMed ID: 24056261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus.
    Smith GE; Flyer DC; Raghunandan R; Liu Y; Wei Z; Wu Y; Kpamegan E; Courbron D; Fries LF; Glenn GM
    Vaccine; 2013 Sep; 31(40):4305-13. PubMed ID: 23891795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.